Literature DB >> 18294334

Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006.

Anders Engeland1, Jørgen G Bramness, Anne Kjersti Daltveit, Marit Rønning, Svetlana Skurtveit, Kari Furu.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Mothers are using medicines during pregnancies; the extent varies across the world and is generally difficult to compare. In this registry-based study, we examined more than 100,000 Norwegian pregnancies and described the drug prescription pattern of both fathers and mothers around conception and during pregnancy (mothers). WHAT THIS STUDY ADDS: In every trimester of pregnancy, about 30% of the mothers was dispensed a drug. The total drug exposure did not seem to diminish throughout pregnancy. One-quarter of the fathers was dispensed drugs during the last 3 months prior to conception. AIMS: The primary aim of this study was to describe the use of prescribed drugs in both mothers and fathers before and during pregnancy in Norway.
METHODS: This population-based cohort study was based on data retrieved from the Medical Birth Registry of Norway and the Norwegian Prescription Database. These registries cover the entire population of Norway. Information on >100,000 births during 2004-2006 in the birth registry was linked to prescription data. Prescriptions issued to mothers just prior to, during and after the pregnancies as well as prescriptions to fathers just prior to conception were identified.
RESULTS: Among mothers, 83% were prescribed drugs during the period 3 months prior to estimated conception until 3 months after giving birth. The mothers who received drugs were prescribed on average 3.3 different Anatomical Therapeutic Chemical (ATC) codes (range 1-38). During pregnancy, 57% were prescribed drugs. In the first trimester, 33% of mothers were dispensed drugs, while the figure was 29% for mothers in the last trimester. Among fathers, 25% used prescribed drugs during the 3 months prior to conception, with on average 1.9 different ATC codes (range 1-22).
CONCLUSION: Large proportions of both fathers and mothers were dispensed drugs prior to conception or during pregnancy. While there is a high awareness of the issues involved in maternal drug use in pregnancy, possible teratogenic effects of drug use in fathers shortly before conception should be further explored.

Mesh:

Year:  2008        PMID: 18294334      PMCID: PMC2432474          DOI: 10.1111/j.1365-2125.2008.03102.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Teratogen update: paternal exposures-reproductive risks.

Authors:  J M Trasler; T Doerksen
Journal:  Teratology       Date:  1999-09

Review 2.  The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years.

Authors:  L M Irgens
Journal:  Acta Obstet Gynecol Scand       Date:  2000-06       Impact factor: 3.636

3.  Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands.

Authors:  M K Bakker; J Jentink; F Vroom; P B Van Den Berg; H E K De Walle; L T W De Jong-Van Den Berg
Journal:  BJOG       Date:  2006-05       Impact factor: 6.531

4.  Drug use among fathers around time of conception: two register based surveys from Denmark and The Netherlands.

Authors:  Eric Schirm; Lars Pedersen; Hilde Tobi; Gunnar L Nielsen; Henrik T Sørensen; Lolkje T W de Jong-van den Berg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-09       Impact factor: 2.890

Review 5.  Epilepsy in pregnancy.

Authors:  Torbjörn Tomson; Vilho Hiilesmaa
Journal:  BMJ       Date:  2007-10-13

Review 6.  Drugs in pregnancy.

Authors:  G Koren; A Pastuszak; S Ito
Journal:  N Engl J Med       Date:  1998-04-16       Impact factor: 91.245

7.  Ethical framework for observational studies of medicinal drug exposure in pregnancy.

Authors:  Gideon Koren
Journal:  Teratology       Date:  2002-04

8.  Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics.

Authors:  J T Mortensen; J Olsen; H Larsen; J Bendsen; C Obel; H T Sørensen
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

9.  Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

Authors:  Christina D Chambers; Sonia Hernandez-Diaz; Linda J Van Marter; Martha M Werler; Carol Louik; Kenneth Lyons Jones; Allen A Mitchell
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population.

Authors:  Ute Amann; Veronika Egen-Lappe; Christine Strunz-Lehner; Joerg Hasford
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-05       Impact factor: 2.890

View more
  67 in total

1.  Drug exposure and pregnancy outcome in Mozambique.

Authors:  Esperança Sevene; Azucena Bardají; Alda Mariano; Sónia Machevo; Edgar Ayala; Betuel Sigaúque; John J Aponte; Xavier Carné; Pedro L Alonso; Clara Menendez
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland.

Authors:  Linda Irvine; Robert W V Flynn; Gillian Libby; Iain K Crombie; Josie M M Evans
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

3.  Drug use in pregnancy--physicians' evaluation of quality and clinical impact of drug information centres.

Authors:  Sofia Kristina Frost Widnes; Jan Schjøtt
Journal:  Eur J Clin Pharmacol       Date:  2008-12-04       Impact factor: 2.953

4.  Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers.

Authors:  Ulrika Nörby; Karin Källén; Birgit Eiermann; Seher Korkmaz; Birger Winbladh; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2012-09-26       Impact factor: 2.953

5.  EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication.

Authors:  Johannes M Luteijn; Joan K Morris; Ester Garne; Joanne Given; Lolkje de Jong-van den Berg; Marie-Claude Addor; Marian Bakker; Ingeborg Barisic; Miriam Gatt; Kari Klungsoyr; Anna Latos-Bielenska; Nathalie Lelong; Vera Nelen; Amanda Neville; Mary O'Mahony; Anna Pierini; David Tucker; Hermien de Walle; Awi Wiesel; Maria Loane; Helen Dolk
Journal:  Br J Clin Pharmacol       Date:  2016-08-04       Impact factor: 4.335

6.  Prescribing in pregnancy and lactation.

Authors:  E J Begg
Journal:  Br J Clin Pharmacol       Date:  2008-05       Impact factor: 4.335

7.  Drug exposure during the periconceptional period: a study of 1793 women.

Authors:  Elisabeth Autret-Leca; Jean Deligne; Joffray Leve; Agnès Caille; Hawaré Cissoko; Annie Pierre Jonville-Bera
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

8.  Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.

Authors:  Sengwee Toh; Qian Li; T Craig Cheetham; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; De-Kun Li; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; William V Bobo; Jean M Lawrence; Inna Dashevsky; Katherine Haffenreffer; Lyndsay A Avalos; Susan E Andrade
Journal:  Arch Womens Ment Health       Date:  2013-02-07       Impact factor: 3.633

9.  Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States.

Authors:  Brian T Bateman; Sonia Hernandez-Diaz; James P Rathmell; John D Seeger; Michael Doherty; Michael A Fischer; Krista F Huybrechts
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

10.  Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets.

Authors:  Sofia Frost Widnes; Jan Schjøtt; Geir Egil Eide; Anne Gerd Granas
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.